# US 2021/0330759 A1 · Methods and compositions for treating cytokine storm, ards, and acute lung injury using beta-glucocerebrosidase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330759 A1
- Document ID: US20210330759A1
- Status: Published application
- Kind: A1
- Application number: 17/234,301
- Filed: 2021-04-19
- Published: 2021-10-28
- Earliest claimed: 2020-04-22
- Applicants: The Cleveland Clinic Foundation
- Inventors: Xiaoxia Li; Junjie Zhao; Quanri Zhang
- Web page: https://patentgrep.com/patent/US20210330759A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- C12Y 302/01045: Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present invention relates to methods and compositions for treating a subject with a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI), using a composition comprising β-glucocerebrosidase, or a vector encoding β-glucocerebrosidase. In certain embodiments, the condition is caused by COVID-19 virus infection or other viral infection.

## Claims

### Claim 1

A method of treating a subject comprising:
administering or providing a composition to a subject,
wherein said composition comprises β-glucocerebrosidase, or a vector encoding β-glucocerebrosidase, and
wherein said subject a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI).

### Claim 2 (depends on 1)

The method of claim 1, wherein said condition is caused by COVID-19 (SARS-CoV-2) virus infection.

### Claim 3 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein said condition is caused by SARS-CoV-1.

### Claim 5 (depends on 1)

The method of claim 1, wherein said condition is caused by a virus.

### Claim 6 (depends on 5)

The method of claim 5, wherein said virus is a coronavirus.

### Claim 7 (depends on 5)

The method of claim 5, wherein said virus is influenza virus.

### Claim 8 (depends on 5)

The method of claim 5, wherein said virus is a virus that causes respiratory illness.

### Claim 9 (depends on 1)

The method of claim 1, wherein said composition is in the form of an aqueous solution and wherein said administering is via intravenous injection into said subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein said administering is via said subject's airway.

### Claim 11 (depends on 1)

The method of claim 1, wherein said composition is administered via said subject's airway using a nebulizer or inhaler.

### Claim 12

An in vitro composition comprising:
a) β-glucocerebrosidase, or a vector encoding β-glucocerebrosidase, and
b) a respiratory virus.

### Claim 13 (depends on 12)

The in vitro composition of claim 12, further comprising human cells.

### Claim 14 (depends on 12)

The in vitro composition of claim 12, wherein said respiratory virus comprises a Coronavirus.

### Claim 15 (depends on 14)

The in vitro composition of claim 14, wherein said Coronavirus comprises Sars-CoV-2 or Sars-CoV-2.

### Claim 16

A system or kit comprising:
a) an airway administration device, and
b) a composition comprising β-glucocerebrosidase, or a vector encoding β-glucocerebrosidase.

### Claim 17 (depends on 16)

The system or kit of claim 16, wherein said airway administration device comprises an inhaler or nebulizer.

### Claim 18 (depends on 16)

The system or kit of claim 16, wherein said composition is present inside said airway administration device.